Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).

GarcĂ­a-GarcĂ­a HM, Garg S, Brugaletta S, Morocutti G, Ratner RE, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Nesto RW, Serruys PW, APPROACH study group

Gestational diabetes: implications for cardiovascular health.

Sullivan SD, Umans JG, Ratner R

Genetic predictors of weight loss and weight regain after intensive lifestyle modification, metformin treatment, or standard care in the Diabetes Prevention Program.

Delahanty LM, Pan Q, Jablonski KA, Watson KE, McCaffery JM, Shuldiner A, Kahn SE, Knowler WC, Florez JC, Franks PW, Diabetes Prevention Program Research Group

Effects of genetic variants previously associated with fasting glucose and insulin in the Diabetes Prevention Program.

Florez JC, Jablonski KA, McAteer JB, Franks PW, Mason CC, Mather K, Horton E, Goldberg R, Dabelea D, Kahn SE, Arakaki RF, Shuldiner AR, Knowler WC, Diabetes Prevention Program Research Group

Genetic modulation of lipid profiles following lifestyle modification or metformin treatment: the Diabetes Prevention Program.

Pollin TI, Isakova T, Jablonski KA, de Bakker PI, Taylor A, McAteer J, Pan Q, Horton ES, Delahanty LM, Altshuler D, Shuldiner AR, Goldberg RB, Florez JC, Franks PW, Diabetes Prevention Program Research Group

Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096).

Ratner R, Wynne A, Nakhle S, Brusco O, Vlajnic A, Rendell M

Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience.

Mete M, Wilson C, Lee ET, Silverman A, Russell M, Stylianou M, Umans JG, Wang W, Howard WJ, Ratner RE, Howard BV, Fleg JL

The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.

Aroda VR, Ratner R

Menopause and risk of diabetes in the Diabetes Prevention Program.

Kim C, Edelstein SL, Crandall JP, Dabelea D, Kitabchi AE, Hamman RF, Montez MG, Perreault L, Foulkes MA, Barrett-Connor E, Diabetes Prevention Program Research Group

Hypertension complicating diabetic pregnancies: pathophysiology, management, and controversies.

Sullivan SD, Umans JG, Ratner R

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.

Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B, LEAD-3 (Mono) Study Group

Diabetes management in the age of national health reform.

Ratner RE

Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes.

Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, Ratner RE, Orchard TJ

Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?

Sullivan SD, Ratner RE

Pioglitazone for diabetes prevention in impaired glucose tolerance.

DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD, ACT NOW Study